Contact Information
38 the FenwayBoston, MA 02215
Phone: 617-536-0220
Fax: 617-536-0657
Email: jjosephson@replikins.com
Website: http://www.replikins.com
Replikins Company Profile
Replikins, Ltd. develops and markets novel forecasting tools and synthetic vaccines to fight virulent rapidly replicating diseases including bird flu, malaria, and HIV. The company's predictive products and vaccines in development are based upon the company's discovery of Replikins, a new group of peptides related to the rapid replication function in viral and other diseases. The company has designed unique products to predict the emergence of virulent strains of particular diseases (FluForecastâ„¢) and is designing synthetic vaccines specifically tailored to combat a given strain and against shared properties of several strains (Syntopeâ„¢ vaccines). The company is partnering with governments and the private sector in providing predictive tools and vaccines in furtherance of the public health initiative to prevent and combat epidemics.News from Replikins:
Current H5N1 Flu Outbreak and Location Predicted in 2009
Cambodian Avian Flu Marks Fifth Time an Increase in the Flu Strain’s Replikins Count® Foretold a (Preventable) Viral Outbreak
LONDON, Feb. 10, 2012 — Bioradar UK Ltd. reported today the fifth instance in which the specific…
FAO Warnings Follow Rise in Replikins Count for Both H5N1 and Swine Flu (H1N1); Replikins Synthetic TransFlu™ Vaccine Tested
U.N. Food and Agriculture Organization Warns of ‘Possible Major Resurgence’ of Avian Flu (H5N1) in Asia and a New Vaccine-Evading Strain in Vietnam and China
LONDON, Aug. 31 2011 — The possible combination of influen…
U.N. Food and Agriculture Organization Warns of ‘Possible Major Resurgence’ of Avian Flu (H5N1) in Asia and a New Vaccine-Evading Strain in Vietnam and China
FAO Warnings Follow Rise in Replikins Count for Both H5N1 and Swine Flu (H1N1); Replikins Synthetic TransFlu™ Vaccine Tested
LONDON, Aug. 31 2011 — The possible combination of influenza strains H1N1 (high infectivity) and H5N1…
Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak
Synthetic Replikins Therapeutics for E. Coli Now Available for Testing
LONDON, June 20, 2011 — Scientists Drs. Samuel and Elenore Bogoch of BioRadar UK Ltd. announced that retrospective studies indicate that an increase in Repli…
New Finding of Rise in H5N1 Virus (Avian Flu) Replikin Count
Replikins Global BioRadar Surveillance System™ Shows Replikin Count in H5N1 at Record High for 2010
BOSTON, Oct. 27, 2010 — BioRadar™ software correctly predicted the 2009 H1N1 (Swine Flu) outbreak a year in advance (http://…
Current Severe Outbreaks of Foot and Mouth Disease Predicted by Replikins’ BioRadar(TM) One Year in Advance (June 2009)
Replikins TransFoot and Mouth Disease (FMD) Vaccine(TM) Now Available; Highest Replikin Count in FMDV in 52 Years Found in 2009
LONDON, July 16, 2010 — BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Diseas…
Both H5N1 Bird Flu and H1N1 Swine Flu Replikin Counts(TM) Are Increasing
H5N1 Outbreaks, Predicted One Year Ago by BioRadar(TM), Now Appear in 63 Countries; TransFlu(TM) Vaccine Shown Effective Against H5N1 in Chickens
LONDON, April 9, 2010 — The most recent BioRadarTM (FluForecastTM) analysis of th…
Replikins’ BioRadar(TM) Announced by UK Trade and Investment
Flu Pandemic Warning Company Sets Up in UK
LONDON, March 29, 2010 — UK Trade and Investment (http://www.newsroom.uktradeinvest.gov.uk/news.ashx) has announced the formation of BioRadar UK Limited. BioRadar is building on the…
Biological H1N1 Vaccines: Too Little, Too Late
Lethality of H1N1 Virus Drops to “Non-Epidemic Resting Levels” in Current Cycle – Virus’ Infectivity Remains Increased; New Faster-Developed Synthetic Replikin Vaccines Found Effective, FluForecast(R)…
New Non-Biological Synthetic Replikins(TM) Vaccines Shown to Be Effective and Fast; WorldVaccines(TM), Ltd Formed for Testing and Distribution
Old Biological Vaccines for Emergent Diseases — Too Little, Too Late
BOSTON, Oct. 19, 2009 — There is increasing evidence that, with best intent, current biological technology cannot supply the world’s six billion h…